{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:31:28Z","timestamp":1793853088323,"version":"4.6.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","award":["Alzheimer\u2019s Research UK"],"award-info":[{"award-number":["Alzheimer\u2019s Research UK"]}],"id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001255","name":"Lister Institute of Preventive Medicine","doi-asserted-by":"publisher","award":["Lister Institute of Preventive Medicine"],"award-info":[{"award-number":["Lister Institute of Preventive Medicine"]}],"id":[{"id":"10.13039\/501100001255","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"DOI":"10.1186\/s13024-024-00745-5","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T10:29:59Z","timestamp":1722248999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic potential of APP antisense oligonucleotides for Alzheimer\u2019s disease and down syndrome-related Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"19","author":[{"given":"Srishruthi","family":"Thirumalai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickie","family":"Patani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0056-7587","authenticated-orcid":false,"given":"Christy","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"745_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21:306\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"745_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3233\/JAD-131883","volume":"40","author":"SA Farr","year":"2014","unstructured":"Farr SA, Erickson MA, Niehoff ML, Banks WA, Morley JE. Central and peripheral administration of antisense oligonucleotide targeting amyloid precursor protein improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (APPswe) mice. J Alzheimer\u2019s Dis JAD. 2014;40:1005.","journal-title":"J Alzheimer\u2019s Dis JAD"},{"key":"745_CR3","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ymthe.2018.02.029","volume":"26","author":"JL Chang","year":"2018","unstructured":"Chang JL, Hinrich AJ, Roman B, Norrbom M, Rigo F, Marr RA, et al. Targeting amyloid-\u03b2 precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-\u03b2 production. Mol Ther. 2018;26:1539\u201351.","journal-title":"Mol Ther"},{"key":"745_CR4","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery CJ, B\u00f6rjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023;29:1437\u201347.","journal-title":"Nat Med"},{"key":"745_CR5","doi-asserted-by":"crossref","unstructured":"Hung C, Fertan E, Livesey FJ, Klenerman D, Patani R. APP antisense oligonucleotides reduce A\u03b2 aggregation and rescue endolysosomal dysfunction in Alzheimer\u2019s disease. Brain. 2024;awae092.","DOI":"10.1093\/brain\/awae092"},{"key":"745_CR6","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1080\/15548627.2021.1963630","volume":"17","author":"C Hung","year":"2021","unstructured":"Hung C, Livesey FJ. Endolysosome and autophagy dysfunction in Alzheimer disease. Autophagy. 2021;17:3882\u20133.","journal-title":"Autophagy"},{"key":"745_CR7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche MA, Hyman BT. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat Neurosci. 2020;23:1183\u201393.","journal-title":"Nat Neurosci"},{"key":"745_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper B, Karran E. The cellular phase of Alzheimer\u2019s disease. Cell. 2016;164:603\u201315.","journal-title":"Cell"},{"key":"745_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41582-021-00575-9","volume":"17","author":"S Lempri\u00e8re","year":"2021","unstructured":"Lempri\u00e8re S. Genome-wide association study identifies new risk loci for Alzheimer disease. Nat Rev Neurol. 2021;17:659.","journal-title":"Nat Rev Neurol"},{"key":"745_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","volume":"4","author":"MC Lauffer","year":"2024","unstructured":"Lauffer MC, van Roon-Mom W, Aartsma-Rus A, Collaborative N 1. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun Med. 2024;4:6.","journal-title":"Commun Med"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-024-00745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-024-00745-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-024-00745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T10:30:49Z","timestamp":1722249049000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-024-00745-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1186\/s13024-024-00745-5","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}